Crinetics Pharmaceuticals, Inc. (CRNX)
NMS – Real Time Price. Currency in USD
36.70
+1.71 (4.89%)
At close: Jun 26, 2026, 4:00 PM EDT
37.00
+0.30 (0.82%)
After-hours: Jun 26, 2026, 6:59 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
36.70
+1.71 (4.89%)
At close: Jun 26, 2026, 4:00 PM EDT
37.00
+0.30 (0.82%)
After-hours: Jun 26, 2026, 6:59 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $114.3M significantly exceed its total debt $47.9M, ensuring strong financial flexibility
Total current assets $1.3B exceed Total current liabilities $71.1M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$125.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 18.60 | 6.05 | 10 | |
| Quick ratio | 18.56 | 5.63 | 10 | |
| Debt to Equity | 0.04 | 0.30 | 9.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 5M | 4M | 1M | 8M | 18M |
| Gross Profit | 3M | 3M | -2M | 3M | 13M |
| Operating Income | -168M | -223M | -339M | -517M | -546M |
| Net Income | -164M | -215M | -298M | -465M | -496M |
| EBITDA | -166M | -222M | -336M | -513M | -542M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 1337.2 | 0.93 | 6.0 |
| Next quarter | 13186.13 | 12.27 | 8.5 |
| Current year | 787.51 | 2.94 | 7.0 |
| Next year | 153.38 | 12.46 | 8.5 |
| Weighted average score | 7.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 74.22 | -4.09 | 4.65 | -34.44 | 4.0 |
| Y/Y | 2873.41 | -32.1 | -18.26 | -39.94 | 3.3 |
| 3y average | 183.78 | -41.95 | -17.08 | -49.02 | 3.3 |
| 5y average | 377.95 | -44.78 | -15.88 | -44.28 | 3.3 |
| Weighted average score | 3.5 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |